+91-8668442535

Fragment-based Drug Discovery Market By Service Type (Fragment Screening Technique, Fragment Optimization Technique), By End-User (Biopharmaceutical Companies, Contract Research Organization, Academic And Research Institutions) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

The global fragment-based drug discovery (FDD) market was worth US$ 503.4 million in 2017 and is expected to grow at a compound annual growth rate (CAGR) of 11.8% from 2018 to 2026. In the last two decades, fragment-based drug discovery has emerged as a significant substitute for high-throughput screening (HTS) for the identification of lead compounds for drug discovery. The introduction of novel techniques in the existing fragment-based drug discovery process has reduced the time and cost of production, which has led to a growing demand for fragment-based drug design.

In comparison to HTS, the fragment-based approach requires the screening of fewer compounds and offers more efficient and productive optimization of compounds. The growing uptake of FBDD by biopharmaceutical companies with the aim of cost-effectiveness and high productivity is projected to drive the fragment-based drug discovery market. Furthermore, the use of fragment-based drug discovery has increased the demand for highly specialized and efficient biophysical techniques capable of weak affinity interactions.

These include nuclear magnetic resonance (NMR) spectroscopy, x-ray crystallography, and capillary electrophoresis, among others. Technological advancements in these screening technologies will further drive the growth of the market. North America dominated the global fragment-based drug discovery market owing to high R&D by biopharmaceutical companies for time- and cost-efficient drug discovery techniques. Asia Pacific is projected to grow at the fastest rate during the forecast period due to the number of CROs operating in the region and the growing outsourcing of pharmaceutical manufacturing in the region.

Market Synopsis

Technological advancements to drive the fragment-based drug discovery market

In 2017, NMR spectroscopy and x-ray crystallography were the leading segments in the global fragment-based drug discovery market. NMR spectroscopy is highly productive and efficient due to recent modifications and is the most commonly used technique. Companies such as Abbott Laboratories, Novartis, and Roche are reported to be using NMR spectroscopy for fragment-based drug discovery. X-ray crystallography provides a detailed profile of fragment-binding, and identifying crystal structures has become a high-throughput process with the help of x-ray crystallography.

Moreover, x-ray crystallography is considered the gold standard in orthogonal fragment screening as it confirms the binding of the protein to the target. Other techniques that are extensively used for fragment-based drug discovery are capillary electrophoresis, surface plasmon resonance, mass spectroscopy, and differential scanning fluorimetry. These are expected to witness substantial growth during the forecast period, thereby driving the fragment-based drug discovery market.

Periods of History and Forecast

This research report presents the analysis of each segment from 2016 to 2026, considering 2017as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments was calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The Fragment-based Drug Discovery Market Report provides quantitative analysis as well as current market trends. The market is segmented based on service type, end-user, and geography.

The market is studied in order to understand the current dynamics and future trends in the global fragment-based drug discovery market. The study includes market size and forecasts for all considered segments presented in the report for the period from 2016 to 2026, along with respective compound annual growth rates (CAGRs) for the forecast period from 2018 to 2026, considering 2017 as the base year. The key players currently engaged in the fragment-based drug discovery market include Astex Pharmaceuticals, Charles River Laboratories International, Inc., Evotec AG, Kinetic Discovery Limited, and Alveus Pharmaceuticals Pvt. Ltd., among others.

Key questions are answered in this report.

  • How will the global fragment-based drug discovery market perform during the forecast period from 2018 to 2026?
  • What are the latest trends in the fragment-based drug discovery market and valuable opportunities for key players?
  • Who are the leading players in the global fragment-based drug discovery market?
  • Which is the leading and fastest-growing region in the global fragment-based drug discovery market?
  • What are the drivers and restraints governing the global fragment-based drug discovery market?

Frequently Asked Question:

The market for Fragment-based Drug Discovery Market is expected to reach USD$ 503.4 Mn in 2026.

The Fragment-based Drug Discovery Market is expected to see significant CAGR growth over the coming years, at 11.8%.

The report is forecasted from 2018 -2026.

Astex Pharmaceuticals, Charles River Laboratories International, Inc., Evotec AG, Kinetic Discovery Limited, and Alveus Pharmaceuticals Pvt. Ltd. are some of the major players in the global market.

Astex Pharmaceuticals, Charles River Laboratories International, Inc., Evotec AG, Kinetic Discovery Limited, and Alveus Pharmaceuticals Pvt. Ltd. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Dec 2018
Category:  Pharmaceuticals
Report ID:   59474
Report Format:   PDF
Pages:   120
Rating:    4.4 (49)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support